Medicare Advantage plan exits are the “recovery” trade’s first true stress test—CMS 2027 rate math tightens while only consolidators can recapture

A major Medicare Advantage (MA) insurer has moved from tweaking benefits to shutting down plans for the next contract cycle—an event the market often treats as noise until you map it to 2027 bid mechanics. In Humana’s case, the company said its 2027 MA plan exits are expected to affect ~600,000 members that Humana will try to recapture, a bet that only works if its remaining plan portfolio can absorb volume without sacrificing medical cost performance.

Humana disclosed that it plans to exit additional MA plans for 2027 and expects the exits to affect roughly 600,000 seniors. It also said it will “recapture a significant portion” of the affected volume, citing that it recaptured just over 40% of members affected by its earlier exits. Importantly, the rationale was not described as “star-rating chasing”; it was described as a focus on margin recovery, using plan selection and geographic/benefit adjustments where needed.

This matters for investors because it flips the usual framing. A rate increase can still be “positive” for the category, while the losing plans can still be unprofitable—forcing management to concentrate risk into fewer, better-performing contracts.

CMS projected a net average 2.48% increase in MA plan payments for CY 2027 (over $13 billion). But the payment framework also includes risk-adjustment and coding-related changes that can alter which contracts show profitable bid math at the plan level.

“Supply chain” in MA isn’t physical like semiconductors; it’s operational. When an insurer exits plans or markets, it often concentrates membership into a smaller set of contracts, which can re-shape bargaining power and per-member economics across care delivery networks, specialty referral patterns, and pharmacy benefit workflows. In practical terms, that means downstream vendors tied to value-based care and high-utilization management can see membership mix shift—while vendors whose business depends on broad, low-selectivity enrollment face volume churn.

To see whether insurers can fund a “portfolio clean-up,” look at their underlying scale and profitability trend. Over the last three fiscal years in the consolidated income statements, UnitedHealth Group and Elevance Health show much larger revenue bases than pure-play MA challengers, while Humana shows a narrower scale footprint. That matters because recapture is a margin story: the insurer needs administrative and operating bandwidth to re-route membership and maintain care-management performance while exiting weaker contracts.

This is why the “recovery” narrative can be directionally right for the sector while still failing at the plan level. Humana’s guidance around recapture is effectively admitting that 2027 profitability will be built by concentrating membership and cutting exposure where cost trend outruns the rate-and-risk math.

CMS still projects a positive average 2027 MA payment outlook, but the boundary condition is whether risk-adjustment and documentation rules translate into stable, defendable bid margins at the contract level. Humana’s 2027 plan exits—paired with explicit recapture expectations—suggest the market should treat “recovery” as portfolio construction, not just rate math. The consolidation-versus-retreat split will decide whose 2027 bids survive unlinked documentation headwinds.